New hope for advanced stomach cancer: experimental combo enters phase 3 trial
Disease control
Not yet recruiting
This phase 3 trial tests whether adding the experimental drug JS107 to standard chemo and immunotherapy works better than another immunotherapy combo for people with advanced stomach or gastroesophageal junction cancer that has a specific marker (CLDN18.2). About 600 adults who h…
Phase: PHASE3 • Sponsor: NingBo Junyan Hongshi Biosciences Co., Ltd • Aim: Disease control
Last updated May 26, 2026 10:49 UTC